CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care for GBM,” a recent article reads. “Other anthracyclines have been limited in their ability to fight brain cancers by their inability to cross the blood-brain barrier, but Berubicin’s unique capacity potentially led to significant outcomes in its earliest safety trial conducted by the drug’s initial developer, Reata Pharmaceuticals. In that small-scale phase I clinical trial in 2006, one of the two dozen evaluated patients emerged cancer-free and has remained so over the subsequent years up to today. Nearly half of the trial’s other patients experienced a statistically significant improvement in clinical benefit of stable disease or better.”
To view the full article, visit https://ibn.fm/eJvgc
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
